Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.
The rise of immunotherapy in cancer care has brought with it the challenge of managing adverse events (AEs). But immune-related AEs are known to be a sign that the treatment is working, and an pooled analysis of phase 3 trials involved atezolizumab (Tecentriq), presented during the 2021 American Society of Clinical Oncology Annual Meeting, show that the presence of low-grade AEs can, in fact, predict longer overall survival (OS).
Atezolizumab is currently approved in the first- and second-line settings for advanced non-small cell lung cancer (NSCLC). In an exploratory analysis, investigators pooled data from the IMpower 130, the IMpower 132, and the IMpower 150 studies, which evaluated the anti-PD-L1 agent in various combinations in treatment-naïve patients with nonsquamous stage IV NSCLC. The combinations were:
Analyses of immune-related AEs and survival took place at 1, 3, 6, and 12 months. In total, 2503 patients were included; 1577 in the atezolizumab arm and 926 in the control arm. Study protocols called for treatment interruption or discontinuation of AEs were grade 3 or higher.
Results showed:
The authors concluded that patients with grade 1 and 2 immune-related AEs had the longest OS and those with grade 3 or higher had the shortest, possibly due to discontinuation of therapy. They wrote that the data offer additional support for atezolizumab with chemotherapy in the first-line setting, with or without bevacizumab.
F. Hoffman-LaRoche funded the study.
Reference
Socinski MA, Jotte RM, Cappuzzo F, et al. Pooled analyses of immune-related adverse events (irAEs) and efficacy from thephase 3 trials IMpower130, IMpower132, and IMpower150. J Clin Oncol. 2021; 39(Suppl_15): abstr 9002. DOI: 10.1200/JCO.2021.39.15_suppl.9002
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
2 Commerce Drive
Cranbury, NJ 08512